6 completed, 1 active not recruiting. 4 Phase 1, 4 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 4 |
| Phase 2 | 4 | Completed 3, Active not recruiting 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow UE2343: new trials by email Literature Review of UE2343 trials Research Report on UE2343
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease Xanamem, Placebo - Dementia Moderate, Dementia, Mild | Phase 2 / Phase 3 | Active not recruiting | Actinogen Medical | 247 | 2024-04-12 | 2026-10-21 |
| Xanamem® in Adults With Major Depressive Disorder and Impaired Cognition (XanaCIDD) Xanamem™, Placebo - Major Depressive Disorder, MDD | Phase 2 | Completed | Actinogen Medical | 167 | 2022-11-28 | 2025-01-22 |
| A Double-Blind, Placebo-Controlled, Dose Ranging Study of Xanamem® in Healthy Elderly Volunteers Xanamem® 5 mg, Placebo, Xanamem® 10 mg - Mild Cognitive Impairment, Alzheimer's Disease | Phase 1 / Phase 2 | Completed | Actinogen Medical | 107 | 2021-06-30 | 2025-01-23 |
| Xanamem™ in Healthy Elderly Subjects Xanamem, Matching Placebo - Safety, Peripheral Neuropathy | Phase 1 | Completed | Actinogen Medical | 42 | 2019-01-21 | 2025-01-22 |
| A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu) Xanamem™, Placebo (for Xanamem™) - Dementia, Alzheimer Type | Phase 2 | Completed | Actinogen Medical | 185 | 2017-03-23 | 2025-02-03 |
| Phase I MAD, Fed-Fasted, CSF Study of UE2343 in Healthy Subjects UE2343, Placebo - Healthy Volunteers | Phase 1 | Completed | Actinogen Medical | 40 | 2015-02-01 | 2025-01-22 |
| A Phase I Study of Oral UE2343 in Healthy Subjects UE2343, Placebo - Healthy | Phase 1 | Completed | University of Edinburgh | 48 | 2013-01-01 | 2013-07-17 |
Cognitive Dysfunction (3) · Alzheimer Disease (2) · Dementia (2) · Depressive Disorder, Major (1) · Lymphoma, Follicular (1) · Peripheral Nervous System Diseases (1) · Small Fiber Neuropathy (1)
Actinogen Medical (6) · University of Edinburgh (1)
Australia (6) · United Kingdom (3) · United States (2)
Bill Ketelbey, MD (2) · Alan Boyd, MD, FFPM (1) · Brian R Walker, BSc MBChB MD (1) · Janakan Krishnarajah (1) · Miriam Roesner (1) · Vincent Ruffles (1)